Key result
Statin use reaches ~71%, yet only one-third of primary prevention patients achieve LDL-C targets.
Cohort (n=332,975)
Answers are grounded in this paper and cite their sources.
Despite increasing statin utilization over nearly two decades, significant gaps remain in treatment intensity and LDL-C target attainment among patients with diabetes and non-dialysis CKD.
Background: With evolving treatment targets, concerns over renal safety for some statins and new lipid-lowering drugs (LLDs), we aimed to evaluate the trends of statins and non-statin LLDs [ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)] utilization in individuals with diabetes and non-dialysis chronic kidney disease (CKD) in Hong Kong. Methods: We conducted a retrospective cohort study of 332,975 Chinese individuals with diabetes and non-dialysis CKD using data from Hong Kong Hospital Authority in 2002-2019. We analyzed the annual average dosage, treatment intensity (low-intensity: <30% Low density lipoprotein-cholesterol (LDL-C) reduction; moderate-intensity: 30%-49%; high-intensity: ≥50%) and attained LDL-C targets defined by annual average LDL-C value. We evaluated the age-sex standardized trends of statin and common non-statin LLD use for primary and secondary prevention across age, sex and CKD stages. Findings: Statin-users increased from 17.6% in 2002 to 71.3% in 2019 with similar trends across age, sex and CKD stages G3-5 except for the 18-49 age group having the highest proportion of non-users of LLD (39%). By 2019, the usage of ezetimibe (1.19%) and PCSK9i (0.01%) remained low. Amongst statin-users, 27.2% received moderate-intensity therapy for primary prevention and 11.2% received high-intensity therapy for secondary prevention. In 2019, 33.3% of LLD-users achieved LDL-C < 1.8 mmol/L for primary prevention and 21.3% achieved LDL-C < 1.4 mmol/L for secondary prevention. Interpretation: Despite the increasing use of statins, treatment gaps remain with respect to treatment intensity and LDL-C target attainment in diabetes and non-dialysis CKD calling for increased use of combination statin and ezetimibe or PCSK9i to close the treatment gaps. Funding: Dr. Aimin Yang was supported by a CUHK Impact Research Fellowship Scheme.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a cohort in diabetes and non-dialysis chronic kidney disease (n=332,975). Lipid-lowering drugs was evaluated on Statin utilization. Statin utilization increased from 17.6% in 2002 to 71.3% in 2019, yet only 33.3% achieved primary prevention LDL-C targets by 2019.
Synapse has enriched 10 related papers. Consider them for comparative context: